Deep Vein Thrombosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major deep vein thrombosis markets reached a value of US$ 458.6 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 905.9 Million by 2034, exhibiting a growth rate (CAGR) of 6.38% during 2024-2034.
The deep vein thrombosis market has been comprehensively analyzed in IMARC's new report titled "Deep Vein Thrombosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Deep vein thrombosis (DVT) refers to a medical condition characterized by the formation of a blood clot in a deep vein, most commonly in the leg. This can happen when blood flow is slowed down or blocked, allowing blood cells and platelets to stick together and form a clot. The symptoms of the ailment vary depending on the intensity and location of the blood clot, but typical signs include swelling, pain, tenderness in the affected area, etc. If the blood clot reaches the lungs and causes a pulmonary embolism, several indications may appear, such as shortness of breath, chest pain, rapid breathing, coughing up blood, etc. Diagnosing deep vein thrombosis typically involves a physical examination, medical history review, and diagnostic tests. During a physical exam, a healthcare provider will look for signs of swelling, pain, and tenderness in the affected area. They may use a handheld Doppler device to listen for changes in blood flow. Various other procedures, such as a D-dimer blood test or venous ultrasound, are also utilized to confirm the diagnosis.
The rising cases of venous stasis owing to several causes, such as prolonged immobility, recent surgery, pregnancy, obesity, etc., are primarily driving the deep vein thrombosis market. In addition to this, the growing prevalence of various associated risk factors, including medical conditions that increase the likelihood of blood clotting, family history of blood clots, use of certain drugs like hormonal birth control, etc. Moreover, the escalating utilization of numerous anticoagulant medications, such as apixaban, rivaroxaban, dabigatran, etc., for preventing the formation of new blood clots and reducing the chances of existing clots getting bigger is also creating a positive outlook for the market. Apart from this, the widespread adoption of compression stockings as a preventative measure or as part of the treatment to improve blood flow is further bolstering the market growth. Additionally, the emerging popularity of inferior vena cava (IVC) filters among patients who cannot tolerate anticoagulant therapy, are at a high risk of bleeding, or have a recurrent DVT despite adequate anticoagulation is acting as another significant growth-inducing factor. Furthermore, the shifting preferences from traditional anticoagulants towards novel anticoagulants, such as betrixaban and edoxaban, owing to their numerous benefits including fewer drug interactions and more convenient dosing schedules, are expected to drive the deep vein thrombosis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the deep vein thrombosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for deep vein thrombosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the deep vein thrombosis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the deep vein thrombosis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the deep vein thrombosis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current deep vein thrombosis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the deep vein thrombosis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the deep vein thrombosis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the deep vein thrombosis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of deep vein thrombosis across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of deep vein thrombosis by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of deep vein thrombosis by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with deep vein thrombosis across the seven major markets?
What is the size of the deep vein thrombosis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of deep vein thrombosis?
What will be the growth rate of patients across the seven major markets?
Deep Vein Thrombosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for deep vein thrombosis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the deep vein thrombosis market?
What are the key regulatory events related to the deep vein thrombosis market?
What is the structure of clinical trial landscape by status related to the deep vein thrombosis market?
What is the structure of clinical trial landscape by phase related to the deep vein thrombosis market?
What is the structure of clinical trial landscape by route of administration related to the deep vein thrombosis market?
The deep vein thrombosis market has been comprehensively analyzed in IMARC's new report titled "Deep Vein Thrombosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Deep vein thrombosis (DVT) refers to a medical condition characterized by the formation of a blood clot in a deep vein, most commonly in the leg. This can happen when blood flow is slowed down or blocked, allowing blood cells and platelets to stick together and form a clot. The symptoms of the ailment vary depending on the intensity and location of the blood clot, but typical signs include swelling, pain, tenderness in the affected area, etc. If the blood clot reaches the lungs and causes a pulmonary embolism, several indications may appear, such as shortness of breath, chest pain, rapid breathing, coughing up blood, etc. Diagnosing deep vein thrombosis typically involves a physical examination, medical history review, and diagnostic tests. During a physical exam, a healthcare provider will look for signs of swelling, pain, and tenderness in the affected area. They may use a handheld Doppler device to listen for changes in blood flow. Various other procedures, such as a D-dimer blood test or venous ultrasound, are also utilized to confirm the diagnosis.
The rising cases of venous stasis owing to several causes, such as prolonged immobility, recent surgery, pregnancy, obesity, etc., are primarily driving the deep vein thrombosis market. In addition to this, the growing prevalence of various associated risk factors, including medical conditions that increase the likelihood of blood clotting, family history of blood clots, use of certain drugs like hormonal birth control, etc. Moreover, the escalating utilization of numerous anticoagulant medications, such as apixaban, rivaroxaban, dabigatran, etc., for preventing the formation of new blood clots and reducing the chances of existing clots getting bigger is also creating a positive outlook for the market. Apart from this, the widespread adoption of compression stockings as a preventative measure or as part of the treatment to improve blood flow is further bolstering the market growth. Additionally, the emerging popularity of inferior vena cava (IVC) filters among patients who cannot tolerate anticoagulant therapy, are at a high risk of bleeding, or have a recurrent DVT despite adequate anticoagulation is acting as another significant growth-inducing factor. Furthermore, the shifting preferences from traditional anticoagulants towards novel anticoagulants, such as betrixaban and edoxaban, owing to their numerous benefits including fewer drug interactions and more convenient dosing schedules, are expected to drive the deep vein thrombosis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the deep vein thrombosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for deep vein thrombosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the deep vein thrombosis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the deep vein thrombosis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the deep vein thrombosis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current deep vein thrombosis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the deep vein thrombosis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the deep vein thrombosis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the deep vein thrombosis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of deep vein thrombosis across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of deep vein thrombosis by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of deep vein thrombosis by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with deep vein thrombosis across the seven major markets?
What is the size of the deep vein thrombosis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of deep vein thrombosis?
What will be the growth rate of patients across the seven major markets?
Deep Vein Thrombosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for deep vein thrombosis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the deep vein thrombosis market?
What are the key regulatory events related to the deep vein thrombosis market?
What is the structure of clinical trial landscape by status related to the deep vein thrombosis market?
What is the structure of clinical trial landscape by phase related to the deep vein thrombosis market?
What is the structure of clinical trial landscape by route of administration related to the deep vein thrombosis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 DEEP VEIN THROMBOSIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 DEEP VEIN THROMBOSIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 DEEP VEIN THROMBOSIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 DEEP VEIN THROMBOSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 DEEP VEIN THROMBOSIS - UNMET NEEDS
10 DEEP VEIN THROMBOSIS - KEY ENDPOINTS OF TREATMENT
11 DEEP VEIN THROMBOSIS - MARKETED PRODUCTS
11.1 List of Deep Vein Thrombosis Marketed Drugs Across the Top 7 Markets
11.1.1 Arixtra (Fondaparinux sodium) - Sanofi aventis
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Fragmin (Dalteparin sodium) - Pfizer
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Eliquis (Apixaban) - Bristol-Myers Squibb/Pfizer
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Savaysa (Edoxaban) - Daiichi Sankyo Company
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Xarelto (Rivaroxaban) - Bayer/Johnson & Johnson
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 DEEP VEIN THROMBOSIS - PIPELINE DRUGS
12.1 List of Deep Vein Thrombosis Pipeline Drugs Across the Top 7 Markets
12.1.1 Abelacimab - Anthos Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. DEEP VEIN THROMBOSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. DEEP VEIN THROMBOSIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 DEEP VEIN THROMBOSIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Deep Vein Thrombosis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Deep Vein Thrombosis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Deep Vein Thrombosis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Deep Vein Thrombosis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Deep Vein Thrombosis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Deep Vein Thrombosis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Deep Vein Thrombosis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Deep Vein Thrombosis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Deep Vein Thrombosis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Deep Vein Thrombosis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Deep Vein Thrombosis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Deep Vein Thrombosis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Deep Vein Thrombosis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Deep Vein Thrombosis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Deep Vein Thrombosis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Deep Vein Thrombosis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Deep Vein Thrombosis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Deep Vein Thrombosis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Deep Vein Thrombosis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Deep Vein Thrombosis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Deep Vein Thrombosis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Deep Vein Thrombosis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Deep Vein Thrombosis - Access and Reimbursement Overview
16 DEEP VEIN THROMBOSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 DEEP VEIN THROMBOSIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 DEEP VEIN THROMBOSIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 DEEP VEIN THROMBOSIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 DEEP VEIN THROMBOSIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 DEEP VEIN THROMBOSIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 DEEP VEIN THROMBOSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 DEEP VEIN THROMBOSIS - UNMET NEEDS
10 DEEP VEIN THROMBOSIS - KEY ENDPOINTS OF TREATMENT
11 DEEP VEIN THROMBOSIS - MARKETED PRODUCTS
11.1 List of Deep Vein Thrombosis Marketed Drugs Across the Top 7 Markets
11.1.1 Arixtra (Fondaparinux sodium) - Sanofi aventis
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Fragmin (Dalteparin sodium) - Pfizer
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Eliquis (Apixaban) - Bristol-Myers Squibb/Pfizer
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Savaysa (Edoxaban) - Daiichi Sankyo Company
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Xarelto (Rivaroxaban) - Bayer/Johnson & Johnson
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 DEEP VEIN THROMBOSIS - PIPELINE DRUGS
12.1 List of Deep Vein Thrombosis Pipeline Drugs Across the Top 7 Markets
12.1.1 Abelacimab - Anthos Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. DEEP VEIN THROMBOSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. DEEP VEIN THROMBOSIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 DEEP VEIN THROMBOSIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Deep Vein Thrombosis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Deep Vein Thrombosis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Deep Vein Thrombosis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Deep Vein Thrombosis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Deep Vein Thrombosis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Deep Vein Thrombosis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Deep Vein Thrombosis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Deep Vein Thrombosis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Deep Vein Thrombosis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Deep Vein Thrombosis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Deep Vein Thrombosis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Deep Vein Thrombosis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Deep Vein Thrombosis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Deep Vein Thrombosis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Deep Vein Thrombosis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Deep Vein Thrombosis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Deep Vein Thrombosis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Deep Vein Thrombosis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Deep Vein Thrombosis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Deep Vein Thrombosis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Deep Vein Thrombosis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Deep Vein Thrombosis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Deep Vein Thrombosis - Access and Reimbursement Overview
16 DEEP VEIN THROMBOSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 DEEP VEIN THROMBOSIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 DEEP VEIN THROMBOSIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
